Metraipolis › archive › dc_30dd625dc423
Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40959072
- DOI
- 10.3389/fimmu.2025.1629224
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T05:53:36.299Z
- SHA-256 of the archived text
3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87- Stable URL of this page
https://metraipolis.com/documento/dc_30dd625dc423
How to cite
Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072 — Europe PMC (en), https://europepmc.org/article/MED/40959072 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_30dd625dc423 (Metraipolis archive dc_30dd625dc423, sha256 3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87)
BibTeX
@misc{dc30dd625dc423,
title = {Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma — Europe PMC PMID:40959072},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40959072},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_30dd625dc423; sha256 3ca0755722cb9bb082e2fd253ef4853877a68a368e0077c5341377daec3add87},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40959072. Agents can read the archived copy with the MCP tool read_document.